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Abstract
The DRSP prevalence rate for the Maltese Islands was
investigated. Consecutive samples were obtained, both from
adults and children, from September 2000 through April 2002.
Penicillin-intermediately-resistant isolates amounted to 27%,
erythromycin-resistant isolates 31%, and clindamycin-resistant
isolates 19%.
The oxacillin disk was found to be an effective screening
method for the detection of penicillin resistance. An association
was found in patients who had DRSP, as well as diabetes and/
or cardiovascular disease. Finally, an investigation of the local
antibiotic consumptions over the period 1997-2000, for the
National Health Service was conducted. The highest
consumption rates were obtained with co-amoxiclav,
amoxicillin, erythromycin, cephalexin and ciprofloxacin.
The results obtained here call for more judicious use of
antibiotics. In addition, the setting up of a local DRSP
surveillance unit is mandatory. Moreover, the use of molecular
techniques to investigate specific genes, such as ermAM and
mefE associated with macrolide-resistance, should be
introduced as part of investigational laboratory work.
Introduction
The first report of acquired bacterial resistance, according
to LP Garrod, dates back to 1937, when a Royal Navy surgeon-
commander, TF Crean, observed a number of refractory cases
of gonorrhoea in a group of patients treated with the
sulphonamide, sulphanilamide (Prontosil®).1 Selection of
bacterial resistance started on a global scale in the early 1940s,
when the first penicillins were introduced in clinical practice.2
Alexander Tomasz described the first penicillin-resistant
pneumococcal isolate, (capsular type 4), isolated from the throat
of a healthy 3-year-old boy in the village of Anguganak, New
Guinea, with a population of 507, on April 15, 1969.3,4 However,
in 1967, Hansman and Bullen described a patient in Sydney,
with hypogammaglobulinemia and bronchiectasis, in whom a
strain of pneumococcus (Type 23) that was relatively insensitive
to penicillin, was isolated from the sputum.5,6
Resistance to ß-lactams in the pneumococcus is mediated
via an intrinsic alteration of high molecular weight penicillin-
binding proteins (PBPs).7 Cephalosporin resistance is due to
alterations in PBP1a and 2x.8
Resistance mechanisms to macrolide, lincosamide (e.g.
clindamycin) and streptograminB (MLS
B
) antibiotics mainly
involve:
a) Target site modification (encoded by ermAM), conferring
broad cross-resistance to MLS
B
 antibiotics and/or
b) Active efflux pump alteration (encoded by mefE). This type
of resistance is confined to structurally-related antibiotics
only.9
Gram-positive bacteria are intrinsically less susceptible to
fluoroquinolones than many Gram-negative bacteria.
Consequentially, bacteria such as Str. pneumoniae typically
require only one or sometimes two mutations in the genes
encoding the target proteins to develop clinical resistance.
Hence, this implies that fluoroquinolone resistance is more
likely to occur.10
The most notoriously, widely spread epidemic clones of
Str. pneumoniae include serotypes 23F, 14, 9V and 6B. 3,4
A report by the United States, Centers for Disease Control
(CDC), for the period April-June 1995, indicated that there was
a great temporal and geographic variation in resistance patterns
and this ranging from 2 to 30%. DRSP may spread quickly
throughout a community and the prevalence rates may differ
between children and adults.11
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Reacher et al12 conducted a study whereby resistant isolates
obtained from blood and reported to the Communicable Disease
Surveillance Centre, during the period 1990 to 1998, were
investigated in England and Wales. It was observed that
penicillin resistance in Str. pneumoniae was below 1% in 1990
and 1991, rising to 3.7% in 1996, reaching a value of 7.4% in
1997 and 3.6% in 1998. Resistance to erythromycin increased
from 5% in 1990, stabilizing at 11% from 1994 onwards.12
In order to investigate the prevalence of DRSP in Asia, the
Asian Network for Surveillance of Resistant Pathogens
(ANSORP) performed a study in which 996 isolates of Str.
pneumoniae were collected from 14 participating hospitals in
12 cities, in 11 Asian countries, during September 1996 to June
1997.13 Analysis of prevalence data for penicillin resistance
revealed a rate of 80% for Korea, (the highest in the world) 13,14,
followed by Japan (65%) and Vietnam (61%).13
Materials and Methods
All consecutive alpha-haemolytic strains isolated routinely
at the Bacteriology Laboratory, St. Luke‘s Hospital, during the
period, September 2000 through April 2002, were obtained.
Samples were obtained both from in- and outpatients.
Cultures were collected in batches and tested randomly. All
samples were coded, in order to protect patient identity.
However, each coded sample could be traced back to the original
patient.
Isolates were identified as Str. pneumoniae by colonial
appearance and standard laboratory tests. Minimum inhibitory
concentrations (MICs) were performed by Etest (AB Biodisk,
Sweden) for penicillin G, erythromycin, clindamycin,
ceftriaxone and vancomycin, in accordance with the
manufacturer‘s instructions.15  Str. pneumoniae ATCC 49619
was used as a control. Oxacillin susceptibility was performed
using 1µg disc on Mueller Hinton Sheep Blood Agar (MH-SBA)
medium (Oxoid, UK). An oxacillin disc diameter of ≤ 19mm
was interpreted to be oxacillin resistant, whilst with ≥ 20mm,
it was taken to be sensitive. Results were read by two
independent observers.
Patients’ files were traced from the Medical Records
Department, after obtaining Ethics Committee approval.
Relevant data such as the diagnosis at the time the sample was
retrieved, concurrent medical conditions, the type of specimen,
age, gender and the antibiotic treatment were noted. Such
parameters were taken in order to investigate any possible
correlation with DRSP and possibly help identify key factors
for resistance.
Table 1: Breakdown of Results
Alpha-Haemolytic Strains Number
of Isolates
Total number of strains tested 129
Viridans streptococci 48
Isolates which showed no growth 5
Pneumococci 76*
Total number of Resistant Pneumococci 37
Multi-Drug-Resistant Isolates
Erythromycin + Clindamycin 18.9% (14/74)
Penicillin + Erythromycin + Clindamycin 8.1% (6/74)
 *Two isolates were excluded as they were obtained from the
same two patients, within 2 days of each other
Table 2: Analysis of Isolates
Antibiotic Sensitive Intermediate Resistant
Penicillin G
MIC Range (µg/ml) ≤0.06 0.12-1.0 ≥2.0
Isolates 73% (54/74) 27% (20/74) 0
Erythromycin
MIC Range (µg/ml) ≤0.5 1.0 ≥2.0
Isolates 68.9% (51/74) 4.1% (3/74) 27 % (20/74)
Clindamycin
MIC Range (µg/ml) ≤0.25 0.5 ≥1.0
Isolates 81.1% (60/74) 0 18.9% (14/74)
Ceftriaxone
MIC Range (µg/ml) ≤0.5 1 ≥2.0
Isolates 100% (74/74) 0 0
Vancomycin
MIC Range (µg/ml) ≤1.0 - -
Isolates 100% (74/74) 0 0
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Antibiotic Consumptions
Antibiotic consumptions for a selected group of antibiotics,
namely those having activity against Str. pneumoniae as well
as DRSP infections, were investigated. Data for the years 1997-
2000 was determined. It must be stated that the values obtained
were restricted only to the National Health Services. Hence, only
the antibiotics, which were consumed within the Maltese Health
Division, including hospitals and pharmacies, were utilized and
did not include antibiotics consumed by the private sector, (i.e.
community pharmacies, which number >200, private hospitals
and clinics). This constitutes a limitation for the data collection.
Antibiotic consumptions were calculated in defined daily
doses/1000 inhabitants/day (DID). The Maltese population
statistics over the period 1997-2000 were obtained from the
Demographic Review, 2000.16  DID values for 1997 were
calculated pro-rata.
Results
As can be viewed in Tables 1-2, from a total of 74
pneumococcal strains, 37 isolates demonstrated resistance to
one or more of the antibiotics tested. Thirty out of sixty-two
(30/62) samples were obtained from sputum, 16/62 from blood,
9/62 from throat-swabs, 5/62 from bronchoalveolar lavage
(BAL) whilst 2/62 were cerebrospinal fluid (CSF) samples.
However,  patient data for 12 cases could not be retrieved from
relevant files.
DRSP Rates
Pneumococcal resistance to penicillin was of the
intermediate type (0.12-1.0µg/ml) and this amounted to 27% .
Erythromycin-resistant isolates accounted for 31.1% of all
pneumococcal isolates. Only 13% of these were intermediately
resistant, the rest i.e. 87% showed high-level resistance,
inferring  ≥ 2.0µg/ml, when incubated in CO
2 
. 15
The total number of clindamycin-resistant isolates equalled
18.9% and all of these were ≥ 1.0µg/ml, i.e. exhibiting high-
level resistance. As was expected, clindamycin-resistant
pneumococcal isolates, were also erythromycin-resistant.
Hence, it can be hypothesised that the MLS
B
 phenotype prevails,
with 61% (14/23) of erythromycin isolates. However, molecular
studies should be performed, proving whether the ermAM gene
is present in such cultures.
Patient Data vs DRSP Rates
Diagnosis at the time of sampling was obtained from patient
files and classified as follows: Respiratory Disease (RD), Other
Diagnosis and Unspecified. In addition, medical histories were
also examined and these were limited to Cardiovascular Disease
(CVD) and Diabetes Mellitus (DM). Respiratory disease
accounted for 71% of DRSP cases, other diagnoses 29%, whilst
13 cases were unspecified.
Statistical analysis of the data obtained was performed by
the Pearson Chi-square Test. The relationship between
erythromycin resistance and RD was found to be statistically
significant (p= 0.0342, n=50).  In contrast, there was no
statistical significance for oxacillin, penicillin and clindamycin
vs diagnosis.
Interestingly, statistical analysis using the same method
revealed that the relationship between CVD vs oxacillin
demonstrated statistical significance (p=0.0241, n=55). In
addition, the relationship between CVD vs penicillin resistance
was also statistically significant (p=0.0241, n=55).
Further analysis proved that the relationship between DM
vs oxacillin resistance was statistically significant (p=0.0241,
n=55). This was consistent with the finding that with DM vs
penicillin resistance revealed statistical significance (p=0.0137,
n=55).
As Str. pneumoniae infections are particularly prevalent in
young children (especially those ≤6 years) and in people aged
≥60 years, it was attempted to investigate whether such an
association could be obtained from our study (Figure 1).
However, no statistical significance was found.
Discussion
The oxacillin disk is a screening method, which is used to
detect penicillin resistance. This method offers a cheap, reliable
method to distinguish between penicillin-resistant and
susceptible isolates. However, it must be stated that the oxacillin
disk does not discern between highly and
intermediatelyresistant isolates.17,18
All pneumococcal isolates were subjected to oxacillin disk
testing. On performing statistical analysis using the Pearson
Chisquare Test (p=0.0000, n=74) it was found that the
relationship between penicillin-resistant isolates and oxacillin-
resistant isolates was highly significant. The findings here are
thus, in accordance with the published literature.17,18
Since resistance to penicillin demonstrated by the
pneumoccoal isolates is of the intermediate type, this infers that
ß-lactams can still be advocated as first-line therapy. However,
the occurrence of intermediately-resistant strains clearly
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Figure 1:  Age Distribution in DRSP cases (n=28)*
*An additional 9 could not be included as, patient file records
  were unavailable
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denotes that a level of caution needs to  be exercised and an
accurate knowledge of the DRSP sensitivity patterns should be
available.
This is particularly imperative, especially in certain life-
threatening conditions, e.g. pneumococcal meningitis.
Third generation cephalosporins (e.g. ceftriaxone,
cefotaxime) are still the mainstay of therapy, for both penicillin-
intermediate and penicillin-resistant strains. In addition,
researchers, advise combination therapy with vancomycin.19-21
As expected, statistical analysis by the Pearson Chisquare
Test (p=0.0000, n=74) revealed that the relationship between
clindamycin and erythromycin resistance was highly significant.
It must be noted that, from the 14 pneumococcal isolates,
which exhibited high-level resistance to clindamycin, 13/14
exhibited an MIC ≥256µg/ml and only one case had an MIC of
1µg/ml (this was still considered as highly resistant).17 Hence,
it can be hypothesized that the ermAM  gene may be found in
these clindamycin-resistant pneumococcal isolates.
Montanari and co-workers22, in Italy found that the ermAM
gene was isolated more frequently that the mefE gene in
erythromycin-resistant isolates. The values obtained were
76.5% for the ermAM gene vs 23.5% for the mefE gene. These
findings were concordant with similar recent studies from
European countries, Japan and South Africa, which also
reflected the percentages, quoted by Montanari et al.22
Lynch refers to the finding that in certain parts of Italy and
Spain ermAM  accounts for more than 80% of macrolide-
resistant strains. In the United States, efflux mechanisms
account for 61% of macrolide resistance (due to mefE) whilst
ribosomal alterations (ermAM) account for 32%.8
One of the patient criteria, which were obtained from
relevant records, was antibiotic treatment. People who were
given antibiotics prior to treatment, i.e., those having a history
of antibiotic usage, as well as those who were given antibiotics
for the current infection, i.e., at the time of sampling, were
included under one heading “Antibiotic Treatment”.
Statistical analysis by the Pearson Chisquare Test
(p=0.0366, n=44) revealed that the relationship between
antibiotic vs erythromycin resistance proved to be statistically
significant. In contrast, no statistical significance was obtained
for Antibiotic Treatment vs penicillin resistance.
Thorvilson and associates23 at the Mayo Clinic, USA,
compared agar dilution, broth dilution, disk diffusion and the
Etest for susceptibility testing of penicillin-susceptible and
penicillin-resistant Str. pneumoniae.
Susceptibility testing was performed on 41 clinical isolates,
as well as the ATCC strain 49619 of Str. pneumoniae. Results
showed that, overall, 71% of strains proved to be penicillin-
intermediately or highly so. When comparing the methods, no
serious errors (i.e., resistant strains falsely interpreted as
susceptible) were observed with any of the media or any method
used. Major interpretative errors (i.e., susceptible strains
interpreted as resistant) were noted only with the disk-diffusion
method.23
Hence, this study is in favour of the Etest as a reliable
method for in vitro susceptibility testing. The study also
mentioned that this test proved to be as efficient as the agar
dilution and broth dilution methods.
MIC interpretation for vancomycin on Brain Heart Infusion
(BHI) medium in our study, proved in most cases to be quite
tedious, as growth was not always very evident on this medium,
possibly due to its transparent nature and hence colonies could
not be differentiated very well. AB Biodisk (Sweden) was
contacted in order to ascertain whether the right medium was
being used and the reply indicated that this was in fact so.
In addition, some values for vancomycin MICs, which were
obtained with the Etest, were quite high i.e., an MIC of
0.75µg/ml and this is indeed very close to the limit for
vancomycin susceptibility, as described by NCCLS, January
2002 of ≤1 µg/ml.
Hashemi and associates in 1996, USA24, tested 37 clinical
pneumococcal isolates, which included 13 penicillin-resistant
(MIC: ≥0.125 µg/ml) and 24 penicillin-susceptible
(MIC: ≤0.06 µg/ml) isolates for vancomycin susceptibility, by
both the Etest and the standard microbroth dilution.
Consequently, it was demonstrated that the Etest resulted
in higher MICs than those obtained with microbroth dilution.
Hashemi advised that MICs obtained with the Etest, which
approached 1µg/ml, should be further investigated by
performing microbroth dilution.24
During MIC determination using the Etest, the medium
used in Hashemi‘s study was not BHI but MH-SBA. Also, the
MICs for the ATCC 49619 control strains, were outside the
acceptable range on 3/5 times in Hashemi‘s study, but was
always within the acceptable range (0.125-0.5 µg/ml) 15 for our
study.
With regard to antibiotic consumptions (Table 3),
ciprofloxacin, with a DID of 0.148, was the fifth most prescribed
antibiotic. Even though ciprofloxacin should not be used as a
first line agent for the treatment of pneumococcal infections,
as evidenced by a number of studies 25-27, it was observed, whilst
examining patient records, that ciprofloxacin had been
prescribed to patients suffering from proven pneumococcal
infections.
Cizman and co-workers28 sought to investigate whether
there was a correlation between the macrolide resistance rates
for Str. pneumoniae and other bacteria, with the macrolide
consumptions in DID over the period 1994-1999, in Slovenia.
This is a small country, with an indigenous population of ca. 2
million people.
Cizman’s study revealed that from 1994-1999 macrolide
consumption increased from 1.89 to 3.84 DID. Interestingly,
this was paralleled by an increase in resistance of
Str. pneumoniae resistance in upper respiratory tract isolates
obtained over this period. Rates increased from 0 to 9% but
there was no significant increase in macrolide resistance in
invasive Str. pneumoniae isolates during this same period.
The authors referred to the fact that in countries exhibiting
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low macrolide consumptions (0.8-2.0 DID), as in Scandinavian
countries, the prevalence of resistance in Str. pneumoniae was
low (<10%), whereas in countries where macrolide
consumptions were high (>3.6 DID), typically France and Spain,
resistance rates were correspondingly high.
Hence, Cizman and associates concluded that a two-fold
increase in the macrolide consumption during the study period
1994-1999, in Slovenia, was associated with a nearly linear
increase in macrolide resistance in upper respiratory
Str. pneumoniae isolates.28
In conclusion, local resistance rates presented here are
definitely an eye-opener. Indeed, following our study, a DRSP
surveillance unit was established in order to monitor such
patterns closely. Ideally, studies like ours should be conducted
over a period of 5-10 years and the data collected correlated
with significant patient factors. Serotyping of all pneumococcal
isolates should be encouraged, especially, in view of the
availability of vaccines and the possibility of acquiring/
developing improved preparations. There should also be an
investment in molecular genetic techniques, in order to clearly
identify specific genes associated with resistance. Finally, stricter
antibiotic policies should be enforced; thereby, reducing the
spread of resistance.
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